Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E, Secker KA, Nitulescu AM, Schairer R, Keppeler H, Wesle A, Schmid H, Schmitt A, Neuber B, Chmiest D, Podavini S, Märklin M, Klimovich B, Schmitt M, Korkmaz F, Lengerke C, Schneidawind C, Schneidawind D. Moraes Ribeiro E, et al. Among authors: schairer r. J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829. J Immunother Cancer. 2024. PMID: 38296597 Free PMC article.
The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.
Erkner E, Hentrich T, Schairer R, Fitzel R, Secker-Grob KA, Jeong J, Keppeler H, Korkmaz F, Schulze-Hentrich JM, Lengerke C, Schneidawind D, Schneidawind C. Erkner E, et al. Among authors: schairer r. Oncogene. 2024 Jan;43(4):281-293. doi: 10.1038/s41388-023-02903-3. Epub 2023 Nov 29. Oncogene. 2024. PMID: 38030791 Free PMC article.
Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R, Secker-Grob KA, Keppeler H, Korkmaz F, Schairer R, Erkner E, Schneidawind D, Lengerke C, Hentrich T, Schulze-Hentrich JM, Schneidawind C. Fitzel R, et al. Among authors: schairer r. Neoplasia. 2023 Jul;41:100902. doi: 10.1016/j.neo.2023.100902. Epub 2023 May 4. Neoplasia. 2023. PMID: 37148657 Free PMC article.
Allosteric activation of MALT1 by its ubiquitin-binding Ig3 domain.
Schairer R, Hall G, Zhang M, Cowan R, Baravalle R, Muskett FW, Coombs PJ, Mpamhanga C, Hale LR, Saxty B, Iwaszkiewicz J, Décaillet C, Perroud M, Carr MD, Thome M. Schairer R, et al. Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):3093-3102. doi: 10.1073/pnas.1912681117. Epub 2020 Jan 24. Proc Natl Acad Sci U S A. 2020. PMID: 31980531 Free PMC article.
GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.
Cheng J, Klei LR, Hubel NE, Zhang M, Schairer R, Maurer LM, Klei HB, Kang H, Concel VJ, Delekta PC, Dang EV, Mintz MA, Baens M, Cyster JG, Parameswaran N, Thome M, Lucas PC, McAllister-Lucas LM. Cheng J, et al. Among authors: schairer r. J Clin Invest. 2020 Feb 3;130(2):1036-1051. doi: 10.1172/JCI97040. J Clin Invest. 2020. PMID: 31961340 Free PMC article.
Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma.
Schröck A, Bode M, Göke FJ, Bareiss PM, Schairer R, Wang H, Weichert W, Franzen A, Kirsten R, van Bremen T, Queisser A, Kristiansen G, Heasley L, Bootz F, Lengerke C, Perner S. Schröck A, et al. Among authors: schairer r. Carcinogenesis. 2014 Jul;35(7):1636-42. doi: 10.1093/carcin/bgu094. Epub 2014 Apr 17. Carcinogenesis. 2014. PMID: 24743512
12 results